Induction with ribavirin in a relapsing patient with chronic HCV hepatitis

Induction with ribavirin in a relapsing patient with chronic HCV hepatitis

Show other versions (1)

In this case, a new possible strategy for treatment of hepatitis C virus (HCV) relapsing patients is described. The target of anti-HCV therapy is sustained viral response, but strategies for improving sustained viral response in relapsing patients would be useful, and ribavirin is crucial for obtain...

Full description

Bibliographic Details
Main Authors:	Claudio Ucciferri, Paola Mancino, Francesca Vignale, Jacopo Vecchiet, Katia Falasca
Format:	Article
Language:	English
Published:	Elsevier 2012-05-01
Series:	Brazilian Journal of Infectious Diseases
Online Access:	http://www.sciencedirect.com/science/article/pii/S1413867012703288

Similar Items

Induction with ribavirin in a relapsing patient with chronic HCV hepatitis
by: Claudio Ucciferri, et al.

USE OF HEMATOPOIETIC GROWTH FACTOR IN THE MANAGEMENT OF HEMATOLOGICAL SIDE EFFECTS ASSOCIATED TO ANTIVIRAL TREATMENT FOR HCV HEPATITIS
by: Paola Mancino, et al.
Published: (2010-03-01)

USE OF HEMATOPOIETIC GROWTH FACTOR IN THE MANAGEMENT OF HEMATOLOGICAL SIDE EFFECTS ASSOCIATED TO ANTIVIRAL TREATMENT FOR HCV HEPATITIS
by: Claudio Ucciferri, et al.
Published: (2010-02-01)

Cystatin C and cardiovascular risk in HIV infected patients
by: Vecchiet Jacopo, et al.
Published: (2010-05-01)

Cardiac toxicity associated with HCV direct antiviral agents
by: Claudio Ucciferri, et al.
Published: (2018-10-01)

Long term effect of telmisartan in HIV-positive male patients with high blood pressure
by: Claudio Ucciferri, et al.
Published: (2015-11-01)

Long term effect of switching to darunavir/ritonavir in HIV infected patients previously on protease inhibitor therapy
by: Claudio Ucciferri, et al.
Published: (2016-07-01)

Effects of dual renin-angiotensin system blockade on proteinuria in a hypertensive black African HIV-infected patient
by: Claudio Ucciferri, et al.
Published: (2011-04-01)

PIDOTIMOD IN PAUCISYMPTOMATIC SARS-CoV2 INFECTED PATIENTS
by: Claudio Ucciferri, et al.
Published: (2020-06-01)

COVID-19 in a patient with SISTEMIC sclerosis: The role of ruxolitinib
by: Claudio Ucciferri, et al.
Published: (2021-09-01)

The impact of homocysteine, B12, and D vitamins levels on functional neurocognitive performance in HIV-positive subjects
by: Katia Falasca, et al.
Published: (2019-02-01)

Clinical characteristics and cardiovascular implications of the dead patients for COVID-19
by: Katia Falasca, et al.
Published: (2021-01-01)

Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection
by: Cody Orr, et al.
Published: (2020-12-01)

Combination of interferon alfa-2b and ribavirin in relapsed or nonresponding chronic hepatitis C patients following interferon therapy
by: Laurentius A. Lesmana, et al.
Published: (2001-11-01)

Chronic HCV treatment with peginterferon-ribavirin and severe tuberculosis re-activation
by: Calza Leonardo, et al.
Published: (2010-05-01)

Analysis of ineffective antiviral therapy with pegylated interferon and ribavirin in a patient with chronic hepatitis C infected with HCV genotype 2
by: O O Znoyko, et al.
Published: (2016-05-01)

Genetic Variability of Hepatitis C Virus (HCV) 5' Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and Ribavirin.
by: Iwona Bukowska-Ośko, et al.
Published: (2015-01-01)

Effect of Probiotic Supplement on Cytokine Levels in HIV-Infected Individuals: A Preliminary Study
by: Katia Falasca, et al.
Published: (2015-09-01)

Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin
by: Guillermo Cabrera Álvarez, et al.
Published: (2011-10-01)

Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy
by: E. Parise, et al.

Standard Interferon and Ribavirin Response in Patients with Chronic Hepatitis C
by: Muhammad Murtaza Bukhari
Published: (2013-12-01)

Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies
by: Suzanne Tavitian, et al.
Published: (2015-08-01)

Predictive factors and prevalence of microalbuminuria in HIV-infected patients: a cross-sectional analysis
by: Katia Falasca, et al.
Published: (2017-07-01)

Weight-based combination therapy with peginterferon alpha-2b and ribavirin for Naïve, relapser and non-responder patients with chronic hepatitis C
by: Fernando Lopes Gonçales Jr., et al.

Parameters associated with diagnosis of COVID‐19 in emergency department
by: Claudio Ucciferri, et al.
Published: (2021-09-01)

Efficacy Of Pegylated Interferon And Ribavirin Treatment In Coinfected HIV HCV Patients
by: Dumitru Irina Magdalena, et al.
Published: (2017-02-01)

Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial
by: Mario G. Pessôa, et al.
Published: (2012-01-01)

The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin
by: K.S. Abdelkawy, et al.
Published: (2020-01-01)

Treatment with ribavirin of hepatitis E virus chronic infection in transplanted patients
by: María Dolores-Antón, et al.
Published: (2015-03-01)

Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
by: Young Kul Jung, et al.
Published: (2013-03-01)

Interferon-ribavirin therapy for chronic hepatitis C: Efficacy in Saudi patients
by: Sandokji Abdulkareem, et al.
Published: (2003-01-01)

Relapse of Vogt-Koyanagi-Harada Disease during Interferon-α and Ribavirin Therapy in a Case of Chronic Viral Hepatitis C
by: Miho Soma, et al.
Published: (2011-01-01)

Using pegylated interferon alfa-2b and ribavirin to treat chronic hepatitis patients infected with hepatitis c virus genotype 1: are nonresponders and relapsers different populations?
by: Giovanni Faria Silva, et al.

Retrospective study of hepatitis c virus relapse after treatment with sofosbuvir and daclatasvir with or without ribavirin
by: Mohamed DA Abd Alla, et al.
Published: (2018-01-01)

Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection
by: Mario Peribañez-Gonzalez, et al.
Published: (2013-03-01)

A phase 2 study of filibuvir in combination with pegylated IFN alfa and ribavirin for chronic HCV
by: Maribel Rodriguez-Torres, et al.
Published: (2014-07-01)

Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection
by: Maribel Rodriguez-Torres, et al.
Published: (2016-11-01)

Review: Rapid virological response to peginterferon alfa and ribavirin treatment of chronic hepatitis C predicts sustained virological response and relapse in genotype 1 patients
by: Fred Poordad, et al.
Published: (2009-03-01)

Individualizing HCV treatment with peginterferon and ribavirin: what needs to be done?
by: Donald M. Jensen
Published: (2009-01-01)

Pegylated interferon, ribavirin, and frequent supportive therapy with growth factors. Which pathogenesis for a severe psoriasis complicating the treatment of chronic HCV hepatitis?
by: Roberto Manfredi
Published: (2009-12-01)